- Home
- UNP vs GILD Comparison
UNP vs GILD Comparison
Compare UNP & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNP | GILD |
|---|---|---|
| Founded | 1862 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.7B | 147.6B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | UNP | GILD |
|---|---|---|
| Price | $239.27 | $120.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 20 |
| Target Price | ★ $259.13 | $127.10 |
| AVG Volume (30 Days) | 3.3M | ★ 7.0M |
| Earning Date | 01-22-2026 | 10-30-2025 |
| Dividend Yield | 2.30% | ★ 2.62% |
| EPS Growth | 8.28 | ★ 6514.05 |
| EPS | ★ 11.78 | 6.42 |
| Revenue | $24,546,000,000.00 | ★ $29,087,000,000.00 |
| Revenue This Year | $2.39 | $3.63 |
| Revenue Next Year | $3.77 | $2.97 |
| P/E Ratio | $20.37 | ★ $18.75 |
| Revenue Growth | 1.06 | ★ 2.79 |
| 52 Week Low | $204.66 | $88.57 |
| 52 Week High | $256.84 | $128.70 |
Technical Indicators
Market Signals| Indicator | UNP | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 67.46 | 44.29 |
| Support Level | $231.50 | $118.78 |
| Resistance Level | $236.77 | $123.74 |
| Average True Range (ATR) | 3.54 | 2.62 |
| MACD | 0.73 | -0.70 |
| Stochastic Oscillator | 98.52 | 15.15 |
Price Performance
Historical ComparisonAbout UNP Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24 billion of revenue in 2024 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).